Moleculin Biotech, Inc. filings document regulatory disclosures for a Delaware clinical-stage pharmaceutical company focused on drug development and commercialization. Recent Form 8-K reports cover Regulation FD releases, investor presentations, financial results, clinical and preclinical updates for Annamycin, and intellectual-property matters involving liposomal Annamycin.
The filing record also includes capital-structure and governance disclosures tied to warrant exercise inducement arrangements, warrant-related share issuance, and stockholder voting matters. Definitive proxy materials and voting results describe special-meeting proposals, including Nasdaq-related approval for warrant shares and charter-related governance items, while exhibit filings attach press releases, presentation materials, and other public-company disclosures.
Moleculin Biotech, Inc. is conducting a reasonable best efforts public offering of up to 4,566,210 shares of common stock, together with Series I common warrants and alternative pre-funded warrants. The registration also covers up to 18,264,840 shares of common stock underlying the pre-funded and common warrants.
The assumed combined public offering price is $2.19 per share (or pre-funded warrant) and accompanying three common warrants, matching the July 27, 2026 Nasdaq closing price. If all securities are sold at this price, net proceeds are estimated at $9.1 million, to advance Annamycin through clinical development and for working capital. Common stock outstanding would increase from 7,100,713 to 11,666,923 shares, with as adjusted net tangible book value of $1.32 per share and immediate dilution of $0.87 per share to new investors.
The offering has no minimum, no escrow and may close with significantly less capital raised, potentially limiting the intended use of proceeds. Common warrants become exercisable only after any required Warrant Stockholder Approval; without such approval they will not be exercisable and will have no value. Interim data from the pivotal MIRACLE Phase 2/3 trial in relapsed/refractory AML showed higher complete remission rates in Annamycin arms versus control, but results are based on a limited sample, are not yet statistically significant and may not predict final outcomes.
Moleculin Biotech, Inc. is registering a reasonable best efforts primary offering of up to 4,566,210 shares of common stock, up to 4,566,210 pre-funded warrants, and 13,698,630 Series I common warrants at an assumed combined price of $2.19 per share or pre-funded warrant plus warrants.
Each share or pre-funded warrant is sold with three common warrants, exercisable at $2.19 for five years beginning on the later of closing or any required Warrant Stockholder Approval; without such approval the common warrants will not be exercisable and will have no value. There is no minimum offering amount, no escrow, and Roth Capital Partners acts as placement agent for a 7% cash fee.
Assuming all securities are sold at the assumed price, Moleculin estimates net proceeds of about $9.1 million, to be used to advance its lead drug Annamycin and for working capital. Shares outstanding would increase from 5,336,350 to 9,902,560, excluding warrant, option and RSU overhang.
The company is conducting the pivotal Phase 2/3 MIRACLE trial in relapsed/refractory AML. A June 2026 interim analysis in 45 patients showed complete remission rates of 43% and 36% in two Annamycin arms versus 12% in control, and composite CR rates of 50% and 57% versus 29%. These results were not statistically significant; the independent data monitoring committee recommended continuing both Annamycin dose arms, and the trial remains designed for 80% power at final analysis. The company states that these interim data may not predict final outcomes and that it will require significant additional financing, beyond this offering, to continue funding its clinical programs.
Moleculin Biotech, Inc. is conducting a reasonable best efforts primary offering of up to 4,566,210 shares of common stock, together with up to 4,566,210 pre-funded warrants, up to 13,698,630 common warrants, and up to 18,264,840 shares underlying those warrants. Each share or pre-funded warrant is offered with three common warrants at an assumed combined price of $2.19.
The company is a late-stage pharmaceutical developer focused on Annamycin (naxtarubicin), a “next‑generation” anthracycline in a pivotal Phase 2/3 MIRACLE trial for relapsed/refractory AML. Interim unblinded results from 45 patients showed higher complete and composite remission rates in both Annamycin arms versus control, but without statistical significance at this stage; the independent monitoring committee recommended continuing the trial.
At the assumed $2.19 price and full take-up, Moleculin projects net proceeds of about $9.1 million, intended mainly to advance Annamycin and for working capital. Common shares outstanding would increase from 5,336,350 to 9,902,560 before any warrant exercises, and new investors would incur immediate book-value dilution.
Moleculin Biotech reported positive preliminary results from the first 45 patients in Part A of its pivotal Phase 2/3 MIRACLE trial in relapsed or refractory acute myeloid leukemia. On a full intent-to-treat basis, both Annamycin arms showed higher remission rates after a single treatment cycle compared with the HiDAC control arm.
The 190 mg/m² and 230 mg/m² Annamycin plus HiDAC arms achieved complete remission rates of 43% and 36%, versus 12% for control. Composite complete remission reached 50% and 57% in the Annamycin arms versus 29% for control. An independent data monitoring committee saw a strong numeric efficacy trend favoring Annamycin and recommended continuing the trial without dropping either dose.
Enrollment in Part A has reached 67 of 90 planned subjects, and efficacy data from Part A are expected to carry into the pivotal Part B analysis. The company notes that these efficacy results are interim, based on a small sample size and not yet statistically significant, and it will need significant additional financing, with no current commitments, to complete its clinical plans.
Moleculin Biotech, Inc. reported that, after filing its quarterly report for the period ended March 31, 2026, investors exercised warrants to purchase 1,361,500 shares of common stock, generating gross proceeds of approximately $2.7 million for the company. As of June 29, 2026, Moleculin Biotech had 7,065,000 shares of common stock outstanding. The company also made available an updated corporate presentation, furnished as Exhibit 99.1.
Moleculin Biotech, Inc. Chief Science Officer Donald H. Picker reported routine equity compensation activity involving restricted stock units (RSUs). On June 20 and June 22, he exercised RSUs to acquire a total of 115 shares of common stock at a conversion price of $0.00 per share.
Across both dates, 34 common shares were withheld at prices of $2.88 and $3.12 per share to cover tax obligations upon RSU vesting, a non‑market disposition. Following these transactions, he directly holds 753 shares of common stock and 19,596 RSUs that convert into common stock on a one‑for‑one basis.
Moleculin Biotech, Inc. CEO and President Walter V. Klemp reported routine equity compensation activity involving restricted stock units and related tax withholding. On June 20 and June 22, restricted stock units converted into a total of 510 shares of common stock at a conversion price of $0.00 per share. To cover tax obligations on these vestings, a total of 125 common shares were disposed of via tax-withholding transactions, rather than open-market sales. After these transactions, Klemp directly held 31,007 shares of common stock and continued to hold a substantial equity position through 326,336 restricted stock units, as well as 250,002 shares of common stock underlying Series E warrants.
Moleculin Biotech, Inc. Chief Financial Officer Jonathan P. Foster reported routine equity compensation activity involving restricted stock units and related tax withholding. On June 20 and June 22, 2026, restricted stock units converted into a total of 283 shares of common stock at a conversion price of $0.00 per share.
To cover tax obligations on these vestings, 72 shares of common stock were disposed of at prices of $2.88 and $3.12 per share through tax-withholding dispositions, not open-market sales. Following these transactions, Foster directly holds 12,340 shares of common stock and 147,718 derivative securities, which include 100,003 shares of common stock underlying Series E warrants.
Moleculin Biotech furnished an update on independent market research evaluating its lead drug candidate Annamycin for relapsed/refractory acute myeloid leukemia. Surveyed oncologists reported an average likelihood-to-prescribe score of 6 out of 7, citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity.
Interviews with hospital administrators and insurers indicated that payers view Annamycin as addressing a significant unmet need, with a potentially meaningful value proposition. Moleculin highlighted that it is a Phase 3 clinical stage company and is advancing the MIRACLE pivotal Phase 2b/3 trial of AnnAraC in R/R AML, while emphasizing that the research sample was small and qualitative and that it will require significant additional financing to conduct its clinical trials.
Moleculin Biotech filed an 8-K to highlight new clinical data on its lead drug candidate Annamycin presented at the 2026 ASCO meeting. A pooled analysis of 90 patients with acute myeloid leukemia and soft tissue sarcoma found no detectable cardiotoxicity, even at cumulative doses far above traditional anthracycline limits.
The analysis used paired left ventricular ejection fraction assessments in 78 patients and was independently reviewed by Cleveland Clinic cardiology specialists. Moleculin views these safety data as strengthening support for its pivotal Phase 2b/3 MIRACLE trial of AnnAraC (Annamycin plus cytarabine) in relapsed or refractory AML, with unblinding of the first 45 patients expected in June 2026.